Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

Shanghai, China, April 10, 2023 - Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma"), a global pharmaceutical company, today announced that there will be five poster presentations showcased at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, April 14-19, 2023. The plasma stability of an antibody-drug conjugate (ADC) is of crucial importance as it impacts both safety and efficacy. The free payload in plasma contributes to certain adverse events that are commonly seen in marketed ADCs. Hengrui Pharma developed a unique ADC platform with an improved molecular design to increase plasma stability and enhance bystander effect. Better safety and efficacy were observed in both preclinical and clinical studies for multiple ADC assets of Hengrui Pharma. These posters will highlight: Superior bystander effect of SHR-A1811, a novel anti-HER2 antibody-drug conjugate (ADC), with optimal drug-antibody ratio (DAR), and favorable safety profiles; Clinical data of SHR-A1811 in phase 1 study for patients with HER2-expressing/mutated advanced solid tumors; Clinical data of SHR-A1811 in phase 1/2 study for patients with advanced HER2-mutant non-small cell lung cancer (NSCLC); An optimized design and well-balanced profile between efficacy and safety of SHR-A1921, a novel TROP-2 ADC; and Clinical data of SHR-A1921 in phase 1 study for patients with advanced solid tumors. Details of the presentations are as follows: Title : SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles Session Title : Late-Breaking Research: Experimental and Molecular Therapeutics 1 Session Date and Time : Sunday April 16, 2023 1:30 PM - 5:00 PM Location : Poster Section 35 Poster Board Number : 23 Abstract Presentation Number : LB031 Title : Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study Session Title : First-in-human Phase 1 Clinical Trials 2 Session Date and Time : Tuesday April 18, 2023 9:00 AM - 12:30 PM Location : Poster Section 45 Poster Board Number : 7 Abstract Presentation Number : CT175 Title : Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multi-center, open-label, phase 1/2 study Session Title : Phase 1 Clinical Trials 1 Session Date and Time : Tuesday April 18, 2023 9:00 AM - 12:30 PM Location : Poster Section 46 Poster Board Number : 17 Abstract Presentation Number : CT204

View stock analysis, news, and events for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A